Here's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back
Investors in Alder Biopharmaceuticals (NASDAQ: ALDR) are having another wild day. Shares of the clinical-stage biopharma rose as much as 15.5% on Thursday after the company released the pricing details of its just announced common-stock offering. As of 12:43 p.m. EDT, the stock was up 13.7%.
Alder stated that it is selling 15 million shares of its common stock for $10 each. In addition, the underwriters of the deal have been granted a 30-day option to purchase up to 2.25 million additional shares at the offering price. The deal is expected to close early next week and could add up to $172.5 million to the company's bank account before subtracting fees.
Image source: Getty Images.
Source: Fool.com
Eli Lilly Corp. Aktie
Die Community ist sich einig: Eli Lilly Corp. nur mit Buy-Einschätzungen, keine Sell-Einschätzungen.
Ein Kursziel von 831 € für Eli Lilly Corp. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 815.0 €.